S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
NASDAQ:PRVB

Provention Bio - PRVB Stock Forecast, Price & News

$8.82
-0.22 (-2.43%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.82
▼
$9.15
50-Day Range
$4.52
▼
$9.50
52-Week Range
$3.18
▼
$9.85
Volume
623,067 shs
Average Volume
1.09 million shs
Market Capitalization
$769.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.40

Provention Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
142.6% Upside
$21.40 Price Target
Short Interest
Bearish
6.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
0.87mentions of Provention Bio in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.66) to ($1.58) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

295th out of 1,034 stocks

Pharmaceutical Preparations Industry

121st out of 504 stocks

See Top Rated MarketRank™ Stocks Here
PRVB stock logo

About Provention Bio (NASDAQ:PRVB) Stock

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Stock News Headlines

December 5, 2022 | finance.yahoo.com
Why Shares of Provention Bio Went Up 30.3% in November
December 1, 2022 | americanbankingnews.com
Provention Bio (NASDAQ:PRVB) Stock Price Down 3.7%
November 25, 2022 | seekingalpha.com
Provention Bio: Assessing The Investment Case After Teplizumab Approval
November 19, 2022 | msn.com
Provention prices diabetes drug above analysts' estimates at $13,850/vial
November 18, 2022 | markets.businessinsider.com
What 5 Analyst Ratings Have To Say About Provention Bio
November 18, 2022 | finance.yahoo.com
Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset
November 18, 2022 | finance.yahoo.com
Provention Bio gets FDA approval for treatment that can delay onset of Type 1 diabetes
November 18, 2022 | investorplace.com
Provention Bio (PRVB) Stock Falls Despite FDA Approval
November 18, 2022 | reuters.com
Provention Bio diabetes drug to cost $13,850/vial
November 18, 2022 | reuters.com
U.S. FDA greenlights Provention Bio's diabetes drug
November 4, 2022 | seekingalpha.com
Provention Bio, Inc. (PRVB) Q3 2022 Earnings Call Transcript
November 3, 2022 | investorplace.com
Why Is Provention Biosciences (PRVB) Stock Up 25% Today?
November 3, 2022 | msn.com
Provention Bio: Q3 Earnings Insights
October 13, 2022 | finance.yahoo.com
Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022
October 12, 2022 | finance.yahoo.com
These 2 Growth Stocks Have Potential Catalysts on the Way
October 6, 2022 | benzinga.com
Thinking about buying stock in Heartbeam, Provention Bio, Pinterest, Quantum-Si, or Palantir Technologies?
October 6, 2022 | markets.businessinsider.com
Why Provention Bio Shares Are Skyrocketing Today
October 6, 2022 | msn.com
Sanofi, Provention Bio Ink Co-Promotion Pact For Type 1 Diabetes Treatment Candidate
October 6, 2022 | nasdaq.com
Provention Bio Announces Collaboration With Sanofi To Expand Commercial Footprint For Teplizumab
October 6, 2022 | finance.yahoo.com
Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
September 22, 2022 | finance.yahoo.com
1 Green Flag and 1 Red Flag for Provention Bio
September 19, 2022 | finance.yahoo.com
Provention Bio Announces Senior Leadership Addition
August 12, 2022 | seekingalpha.com
Provention Bio: More Risk, More Dilution Ahead - Downgrading To A Sell Rating
August 6, 2022 | seekingalpha.com
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2022 Results - Earnings Call Transcript
August 4, 2022 | finance.yahoo.com
Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
See More Headlines
Receive PRVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

PRVB Company Calendar

Last Earnings
11/04/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRVB
CUSIP
N/A
CIK
1695357
Web
www.proventionbio.com
Phone
(908) 428-9136
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.40
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+142.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-114,430,000.00
Net Margins
-3,791.21%
Pretax Margin
-4,043.30%
Return on Equity
-99.08%
Return on Assets
-76.29%

Debt

Debt-to-Equity Ratio
0.16
Current Ratio
7.58
Quick Ratio
7.58

Sales & Book Value

Annual Sales
$1.39 million
Price / Sales
553.26
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.75 per share
Price / Book
5.04

Miscellaneous

Outstanding Shares
87,191,000
Free Float
75,769,000
Market Cap
$769.02 million
Optionable
Not Optionable
Beta
2.40

Key Executives

  • Mr. Ashleigh W. Palmer B.Sc.Mr. Ashleigh W. Palmer B.Sc. (Age 59)
    M.B.A., Co-Founder, Pres, CEO & Director
    Comp: $900.3k
  • Mr. Thierry Chauche (Age 46)
    Chief Financial Officer
    Comp: $411.37k
  • Dr. Eleanor L. Ramos M.D. (Age 66)
    Chief Medical Officer
    Comp: $611.72k
  • Dr. Francisco Leon M.D.Dr. Francisco Leon M.D. (Age 50)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Ms. Christina Yi (Age 46)
    Chief Operations Officer
  • Mr. Robert A. Doody Jr.
    VP of Investor Relations
  • Ms. Heidy Abreu King-Jones J.D. (Age 39)
    L.L.M., Chief Legal Officer
  • Kaelan Hollon
    VP of Corp. Communications
  • Mr. Jason Levine
    VP Marketing
  • Sarah O'Brien
    Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PRVB Stock - Frequently Asked Questions

Should I buy or sell Provention Bio stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRVB shares.
View PRVB analyst ratings or view top-rated stocks.

What is Provention Bio's stock price forecast for 2023?

6 analysts have issued twelve-month price targets for Provention Bio's stock. Their PRVB share price forecasts range from $18.00 to $30.00. On average, they predict the company's stock price to reach $21.40 in the next year. This suggests a possible upside of 142.6% from the stock's current price.
View analysts price targets for PRVB or view top-rated stocks among Wall Street analysts.

How have PRVB shares performed in 2022?

Provention Bio's stock was trading at $5.62 at the beginning of the year. Since then, PRVB shares have increased by 56.9% and is now trading at $8.82.
View the best growth stocks for 2022 here.

When is Provention Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PRVB earnings forecast.

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.08. The firm had revenue of $0.68 million for the quarter, compared to analysts' expectations of $3.75 million. Provention Bio had a negative trailing twelve-month return on equity of 99.08% and a negative net margin of 3,791.21%. During the same period in the previous year, the firm posted ($0.56) earnings per share.

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Who are Provention Bio's major shareholders?

Provention Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.77%), Vanguard Group Inc. (4.13%), State Street Corp (1.48%), Verition Fund Management LLC (0.99%), Bioimpact Capital LLC (0.85%) and Palo Alto Investors LP (0.45%). Insiders that own company stock include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon and Jason Hoitt.
View institutional ownership trends.

How do I buy shares of Provention Bio?

Shares of PRVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $8.82.

How much money does Provention Bio make?

Provention Bio (NASDAQ:PRVB) has a market capitalization of $769.02 million and generates $1.39 million in revenue each year. The company earns $-114,430,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The official website for the company is www.proventionbio.com. The company can be reached via phone at (908) 428-9136 or via email at kimberly@argotpartners.com.

This page (NASDAQ:PRVB) was last updated on 12/9/2022 by MarketBeat.com Staff